H.C. Wainwright raised the firm’s price target on NeuroPace (NPCE) to $19 from $18 and keeps a Buy rating on the shares. The company’s core revenue growth is expected to be 20%-22% in 2026, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NPCE:
- Morning Movers: L3Harris Technologies jumps after DoW investment
- NeuroPace sees FY26 revenue $98M-$100M, consensus $98.44M
- NeuroPace sees Q1 revenue $21M-$22M, consensus $22.35M
- NeuroPace reports preliminary Q4 revenue $26.6M, consensus $24.43M
- NeuroPace Initiated With Buy on Breakthrough RNS Label Expansion Opportunity and Strong NAUTILUS Efficacy Data